Innovation Pharmaceuticals Completes Patient Enrollment in Phase 2 Study of Brilacidin for the Prevention of Severe Oral Mucositis

BEVERLY, Mass., August 7, 2017 (GLOBE NEWSWIRE) – Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces that it has completed patient enrollment for its ongoing Phase 2 clinical study of Brilacidin for the prevention of Severe Oral Mucositis (OM). A total of 61 patients have been enrolled, with topline results anticipated in 4Q2017.

The Company looks forward to completing the study so that the full dataset can be analyzed, further informing Brilacidin’s treatment potential in OM. Previously released interim results, showing a markedly reduced rate of Severe OM (WHO Grade ≥ 3) in patients treated with Brilacidin compared to placebo, can be accessed at the link below.


Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals, said, “The completion of full patient enrollment in our Phase 2 study of Brilacidin marks an important step towards the Company’s goal of potentially developing the first-ever preventative treatment for Severe OM. There currently is a considerable unmet medical need and market opportunity in this area. Brilacidin, which is easily administered via an oral rinse, stands apart from other OM drug candidates in development, as they are mainly intravenously-administered and primarily targeted at only ameliorating OM symptoms.”

About Oral Mucositis

Oral Mucositis (OM) is a frequent, painful and debilitating complication of chemoradiation commonly manifesting in the treatment of Head and Neck Cancer. Characterized by inflammation and ulceration, patients suffering from OM are often unable to speak or eat (requiring the insertion of a feeding tube) and are more susceptible to bacterial infections, with severe cases leading to hospitalization and increased treatment costs of up to $25,000. Affecting over 500,000 people in the United States, there currently are no approved medications for the prevention of OM in this population, with only limited palliative care options available. Worldwide, the potential market for OM is expected to exceed $1 billion in the next few years.